ARTICLE | Clinical News
Tarextumab: Development discontinued
April 21, 2017 8:33 PM UTC
OncoMed said it will discontinue all clinical development of tarextumab after reporting data from 145 previously untreated patients with extensive-stage SCLC in the Phase II portion of the double-blin...
BCIQ Company Profiles